Tests TBI-1301 cell therapy in adults with NY-ESO-1 positive synovial sarcoma
Tests TBI-1301 cell therapy in adults with a certain type of soft tissue cancer.
Plain-language title generated from the registry record
Registry title: Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Key facts
- Where
- Fukuoka, Kashiwa, and Osaka, JapanSee the 3 sites
- Phase
- Phase 3
Where in Japan
- Kyusyu University HospitalFukuoka, JapanTaking people
- National Cancer Center Hospital EastKashiwa, JapanTaking people
- Osaka International Cancer InstituteOsaka, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Takara Bio Inc.
- Trial code
- NCT07174427
- Record updated
- 28 September 2026
- Original description
The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.Read full original descriptionShow less
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
Inclusion: ≥ 18 years of age; Histologically confirmed synovial sarcoma; Surgically unresectable tumor; Progressing or recurrent synovial sarcoma which has been treated with 1-4 regimens of systemic chemotherapies including anthracycline; HLA-A*02:01 or HLA-A*02:06 positive; Tumor that express NY-ESO-1 by immunohistochemistry; Measurable lesions that are evaluable by the RECIST ver1.1; ECOG Performance Status of 0, 1 or 2; No treatment such as chemotherapy and be expected to recover fully from the previous treatment at the time of the lymphocytes collection for manufacturing; Life expectancy ≥ 16 weeks after consent; No severe damage on the major organs (bone marrow, heart, lung, liver, kidney, etc) and meet the following lab value criteria; Total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST(GOT), ALT(GPT) < 3.0 x ULN; Creatinine < 1.5 x ULN; 2,500/μL < WBC ≤ULN; Hemoglobin ≥ 8.0g/dL; Platelets ≥ 75,000/μL; Patients must be able to understand the study contents and to give a written consent at his/her free will.
Exclusion: History of hypersensitivity reaction to ingredients or excipients of investigational drugs used in this study; History of hypersensitivity reaction to antibiotics used in manufacturing for the investigational drug used in this study; History of treatment with cell therapy or gene therapy; Alcohol or drug dependence that may interfere with study participation; Pregnant females, lactating females (except when they cease and do not resume lactation) or female and male patients who cannot agree to practice the adequate birth control from the consent to 6 months after infusion of the investigational drug; Patients with the following conditions are excluded from the study; Unstable angina, cardiac infarction, or heart failure; Uncontrolled diabetes or hypertension; Active infection; Obvious interstitial pneumonia or lung fibrosis by chest X-ray; Active autoimmune disease requiring steroids or immunosuppressive therapy; Active multiple cancer; Positive for antibodies against HIV or HTLV-1; History of serious hypersensitivity reactions to bovine or murine derived substances; Clinically significant systemic illness that in the judgment of the PI or sub-investigator would compromise the patient's ability to tolerate protocol therapy or significantly increase the risk of complications; Positive for HBs antigen or HBV-DNA observed in serum; Positive for HCV antibody and HCV-RNA observed in serum; Active metastatic tumor cell invasion into CNS.